DFIB Cardiac Science (MM)

City of St. Louis Selects Cardiac Science as Exclusive Provider of AEDs for Public Access Defibrillation Program St. Louis Joins a Growing List of Major U.S. Cities to Partner With Cardiac Science on Comprehensive AED Deployment IRVINE, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of life-saving automatic public-access defibrillators (AEDs), announced today that it has been selected as the exclusive provider of AEDs and comprehensive AED/CPR training and AED program management services for a city-wide Public Access Defibrillator (PAD) program launched by the City of St. Louis, Missouri. To initiate the program, approximately 90 Powerheart(R) AED G3s were purchased from Cardiac Science. St. Louis's new PAD program makes it the latest major U.S. city to partner with Cardiac Science, joining San Diego, Minneapolis, Miami and Nashville. "The St. Louis Project Heartbeat" PAD program, which has been approved by the City of St. Louis and Mayor Francis G. Slay, seeks to provide this life saving technology to all its citizens, guests and employees. The PAD program is being coordinated by the St. Louis Fire Department, which in addition to planning the deployment of AEDs, is reaching out to private citizens and organizations through a public awareness campaign on the importance of defibrillation therapy and the use of AEDs to treat victims of a massive heart attack, also called sudden cardiac arrest ("SCA"). According to St. Louis Fire Commissioner and Chief Sherman George, the goal of the PAD project is to significantly increase local community cardiac arrest survival rates by making AEDs more accessible in a wide variety of settings and educating citizens about the Chain of Survival, an emergency intervention process that includes early defibrillation and CPR. "The St. Louis Fire Department has focused on injury and illness prevention in many community outreach programs. This program aims to dramatically improve SCA survival rates in St. Louis," said Chief George. "This program is beneficial not only to our citizens but to our fellow firefighters as well. Heart attacks and SCA remain the number one killers of firefighters today. "Our goal is to deploy hundreds of AEDs in public facilities, highly trafficked public places and businesses throughout St. Louis within the next few years," continued George. "This is a true partnership and we look forward to working with Cardiac Science in this effort. We chose Cardiac Science based on a number of factors. We were impressed with their comprehensive program and a demonstrable track record of PAD program successes in other cities. In addition, we conducted an extensive review of all AED products in the market and found that Cardiac Science's Powerheart AEDs are robust, reliable, and very easy to use and best suited the needs of the St. Louis Fire Department." About Cardiac Science Cardiac Science develops, manufactures and markets Powerheart(R)-brand public-access defibrillators (AEDs) and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The Company also makes its AEDs on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information, please visit http://www.cardiacscience.com/, email Cardiac Science at or call 1-949-797-3800. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward- looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2003, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission. For further information please contact: Matt Clawson (Investors), Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, DATASOURCE: Cardiac Science, Inc. CONTACT: Matt Clawson (Investors), Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright